AnaptysBio Inc Stock
AnaptysBio Inc Stock
The AnaptysBio Inc price is unchanged compared to yesterday.
With 22 Buy predictions and not a single Sell prediction AnaptysBio Inc is an absolute favorite of our community.
As a result the target price of 50 € shows a slightly positive potential of 17.37% compared to the current price of 42.6 € for AnaptysBio Inc.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for AnaptysBio Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of AnaptysBio Inc in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of AnaptysBio Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | 0.000% | 3.902% | 12.105% | 162.963% | -0.930% | 78.992% | 85.783% |
| Ocuphire Pharma Inc. | 1.670% | -13.800% | 20.690% | 96.325% | 20.690% | -37.577% | - |
| Immunic Inc. | -3.250% | 8.235% | 10.843% | -41.214% | 28.372% | -79.279% | -96.344% |
| NanoViricides Inc. | 0.600% | -6.704% | -18.137% | -24.091% | -10.215% | -33.783% | -76.278% |
Comments
AnaptysBio (NASDAQ:ANAB) had its "buy" rating reaffirmed by analysts at Guggenheim.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at Stifel Nicolaus from $80.00 to $56.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio (NASDAQ:ANAB) had its price target lowered by analysts at HC Wainwright from $52.00 to $51.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
News
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally
On Dec. 23, AnaptysBio (NASDAQ:ANAB) Director J. Anthony Ware executed an open-market sale of 3,900 shares for a transaction value of $193,342.50, representing 28.82% of his direct holdings
What Investors Should Know About a $163K AnaptysBio Insider Sale
Paul F. Lizzul, the chief medical officer of AnaptysBio (NASDAQ:ANAB), reported the direct sale of 3,650 shares of the company for a total consideration of approximately $163,191.50 on Thursday, as
AnaptysBio (ANAB) Q2 Revenue Jumps 103%
AnaptysBio (NASDAQ:ANAB), a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, released its Q2 2025 earnings on August 6